Odonate Therapeutics found using ticker (ODT) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The target price ranges between 4 and 4 and has a mean target at 4. With the stocks previous close at 3.28 this is indicating there is a potential upside of 22.0%. There is a 50 day moving average of 3.05 and the 200 moving average now moves to 3.31. The market cap for the company is $127m. Visit the company website at: http://www.odonate.com
Odonate Therapeutics, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.